Assessing the impact of jail-initiated medication for opioid use disorder: A multisite analysis of the SOMATICS collaborative

Joshua D. Lee, Keith Goldfeld, Robert P. Schwartz, Ryan McDonald, Yifan Xu, Redonna Chandler, Kevin Hallgren, Sharon M. Kelly, Shannon Gwinn Mitchell, Anjalee Sharma, David Farabee

Research output: Contribution to journalArticlepeer-review

Abstract

The objective of this study was to estimate the associations of jail-initiated medication for opioid use disorder (MOUD) and patient navigation (PN) with opioid use disorder (OUD) at 6 months post-release. Three randomized trials (combined N = 330) were combined to assess whether MOUD (extended-release naltrexone or interim methadone) initiated prior to release from jail with or without PN would reduce the likelihood of a DSM-5 diagnosis of OUD 6 months post-release relative to enhanced treatment-as-usual (ETAU). Across the three studies, assignment to MOUD compared to ETAU was not associated with an OUD diagnosis at 6 months post-release (69% vs. 75%, respectively, OR = 0.67, 95% CI: 0.42 to 1.20). Similarly, PN compared to MOUD without PN was not associated with an OUD diagnosis (63% vs 77%, respectively, OR = 0.61, 95% CI: 0.27 to 1.53). Results underscore the need to further optimize the effectiveness of MOUD for patients initiating treatment in jail, beginning with an emphasis on post-release treatment adherence.

Original languageEnglish (US)
Article numbere0305165
JournalPloS one
Volume19
Issue number6
DOIs
StatePublished - Jun 2024

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Assessing the impact of jail-initiated medication for opioid use disorder: A multisite analysis of the SOMATICS collaborative'. Together they form a unique fingerprint.

Cite this